|
|
 |
|
Viewing report
|
|
|
|
Pipeline and Commercial Insight: Schizophrenia - Second Generation Depots Protect Market Value
Datamonitor, Oct 2008, Pages: 277
Schizophrenia is a chronic and severe mental health disorder affecting around 4.6 million schizophrenia sufferers across the seven major markets. Currently led by oral branded atypical antipsychotics, the schizophrenia market will undergo some big changes over the period 20082017. Prospective players can expect to face stiff competition from generic versions of all currently branded drugs.
Scope
- Analysis of key marketed brands and late-stage pipeline drugs.
- Schizophrenia-specific drug sales volume and value forecasts to 2017 in the US, Japan, and five major European markets.
- Identification of future market events that are expected to affect schizophrenia drug revenues.
- Analysis of patient potential, unmet needs and clinical trial design in schizophrenia.
Highlights of this title
The schizophrenia market is anticipated to grow slowly until 2011 to reach $4.3 billion across the 7MM. Despite the launch of a few pipeline drugs, the market will decline thereafter owing to the widespread launch of generic risperidone by the end of 2008, followed by generic versions of all currently marketed schizophrenia drugs from 2011 onwards.
The increasing uptake of long-acting injectable (depot) atypical antipsychotics is expected to partially alleviate the branded schizophrenia sales decline. Positive effects on patient compliance will stimulate sales of these formulations which are forecast to reach a combined value of $1.2 billion by 2013.
The schizophrenia late-stage pipeline lacks innovation. Sales of most oral investigational drugs will be limited by extensive generic competition across the 7MM. However, drugs with novel mechanism of action could prove commercially successful, demanding a price premium and offering alternative treatments for refractory patients.
Key reasons to purchase this title
- Understand the current schizophrenia market dynamics and how they are expected to evolve out to 2017.
- Benchmark key late-stage pipeline schizophrenia compounds against the current market leading brands.
- Understand unmet needs and opportunities in the schizophrenia market based on key opinion leader comments.
Customers who bought this item also bought
Pipeline Insight: Schizophrenia
CNS Drug Discoveries: Schizophrenia Chapter
Schizophrenia Market: Novel Agents May Establish New Leaders
Central Nervous System Schizophrenia
Treatment Algorithms 2001: Schizophrenia - The Rise of Atypical Neuroleptics as the Physicians’ Favorite
Pipeline Report - Neuronal alpha 7 nicotinic receptors: Candidates for the treatment of Alzheimers disease and Schizophrenia
CNS Generic Drugs: Prospects and Opportunities to 2012
Generic Drugs Market in Brazil (2007-2011)
Opportunities and Challenges for Bioequivalent Generic Drugs in Brazil
Pipeline Insight: Antipsychotics - Novel Antipsychotics Driving Market Evolution
Drugs of Tomorrow: Antipsychotics - Gaining Competitive Advantage From a Limited Research Base
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
|
|
|
|
